Capital Investment Advisory Services’s GSK GSK Stock Holding History

Capital Investment Advisory Services’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$467K	Buy	8,903 +4,555	+105%	+$241K	0.03%	459
2026 Q1	$240K	Sell	4,348 -2,532	-37%	-$137K	0.02%	577
2025 Q4	$337K	Buy	6,880 +751	+12%	+$35K	0.02%	474
2025 Q3	$265K	Buy	6,129 +13	+0.2%	+$508	0.02%	506
2025 Q2	$235K	Buy	+6,116	New	+$234K	0.02%	516
2024 Q4	–	Sell	-5,646	Closed	-$231K	–	965
2024 Q3	$231K	Sell	5,646 -2,641	-32%	-$108K	0.02%	467
2024 Q2	$319K	Buy	8,287 +1,367	+20%	+$57.5K	0.03%	381
2024 Q1	$297K	Sell	6,920 -723	-9%	-$29.8K	0.03%	404
2023 Q4	$283K	Sell	7,643 -644	-8%	-$23.1K	0.03%	410
2023 Q3	$300K	Buy	8,287 +870	+12%	+$30.9K	0.03%	381
2023 Q2	$264K	Sell	7,417 -486	-6%	-$17.4K	0.03%	393
2023 Q1	$281K	Buy	7,903 +1,455	+23%	+$50.9K	0.03%	374
2022 Q4	$227K	Buy	+6,448	New	+$215K	0.03%	428
2022 Q3	–	Sell	-4,874	Closed	-$265K	–	829
2022 Q2	$265K	Buy	4,874 +851	+21%	+$47K	0.03%	380
2022 Q1	$219K	Buy	+4,023	New	+$219K	0.02%	457
2021 Q3	–	Sell	-5,880	Closed	-$293K	–	781
2021 Q2	$293K	Sell	5,880 -729	-11%	-$35K	0.04%	374
2021 Q1	$295K	Buy	6,609 +948	+17%	+$43K	0.04%	337
2020 Q4	$260K	Sell	5,661 -289	-5%	-$13.3K	0.04%	363
2020 Q3	$280K	Sell	5,950 -191	-3%	-$9.57K	0.05%	288
2020 Q2	$313K	Sell	6,141 -1,249	-17%	-$64.1K	0.06%	240
2020 Q1	$350K	Sell	7,390 -364	-5%	-$19.4K	0.09%	213
2019 Q4	$455K	Buy	7,754 +1,566	+25%	+$87.1K	0.12%	169
2019 Q3	$330K	Sell	6,188 -1,029	-14%	-$52.9K	0.09%	203
2019 Q2	$371K	Buy	7,217 +895	+14%	+$44.9K	0.11%	189
2019 Q1	$330K	Buy	6,322 +605	+11%	+$30.2K	0.12%	153
2018 Q4	$273K	Sell	5,717 -929	-14%	-$45.8K	0.12%	166
2018 Q3	$334K	Buy	6,646 +910	+16%	+$46.2K	0.16%	153
2018 Q2	$289K	Sell	5,736 -106	-2%	-$5.34K	0.14%	163
2018 Q1	$285K	Buy	5,842 +912	+18%	+$42.5K	0.16%	149
2017 Q4	$219K	Buy	+4,930	New	+$228K	0.13%	166

Other funds holding GSK

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

FVWA

Foster Victor Wealth Advisors Greenville, South Carolina $1.9B AUM 24.46% 1-Year Est. Return

SIS

Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return

KFP

Keystone Financial Planning Cleveland, Ohio $388M AUM 16.66% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

Transmarket Holdings Chicago, Illinois $136M AUM

Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

Capital Investment Advisory Services's GSK Position: Q2 2026 in Review

Capital Investment Advisory Services increased its GSK (GSK) stake by 105% in Q2 2026, buying an estimated $241K and bringing the position to 8,903 shares worth $467K. The position accounts for 0.03% of the portfolio, ranked #459.

Capital Investment Advisory Services first reported a position in GSK in Q4 2017 and has held it in 30 quarters since. 265 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Capital Investment Advisory Services held 8,903 shares of GSK worth $467K as of Q2 2026.
Capital Investment Advisory Services bought 4,555 GSK shares in Q2 2026, an estimated $241K.
GSK made up 0.03% of Capital Investment Advisory Services's portfolio in Q2 2026, its #459 holding.
Capital Investment Advisory Services first reported a position in GSK in Q4 2017 and has held it in 30 quarters since.
265 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Capital Investment Advisory Services's 13F filing for Q2 2026, filed 23 Jul 2026.